Katalog der Deutschen Nationalbibliothek
Ergebnis der Suche nach: Thomas and Müller
|
|
|
| Link zu diesem Datensatz | https://d-nb.info/1118728599 |
| Titel | SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial |
| Person(en) |
Rochlitz, Christoph (Sonstige) Bigler, Martin (Sonstige) von Moos, Roger (Sonstige) Bernhard, Jürg (Sonstige) Matter-Walstra, Klazien (Sonstige) Wicki, Andreas (Sonstige) Zaman, Khalil (Sonstige) Anchisi, Sandro (Sonstige) Küng, Marc (Sonstige) Na, Kyung-Jae (Sonstige) Bärtschi, Daniela (Sonstige) Borner, Markus (Sonstige) Rordorf, Tamara (Sonstige) Rauch, Daniel (Sonstige) Müller, Andreas (Sonstige) Ruhstaller, Thomas (Sonstige) Vetter, Marcus (Sonstige) Trojan, Andreas (Sonstige) Hasler-Strub, Ursula (Sonstige) Cathomas, Richard (Sonstige) Winterhalder, Ralph (Sonstige) |
| Organisation(en) |
on behalf of the Swiss Group for Clinical Cancer Research (SAKK) (Verfasser) SpringerLink (Online service) (Sonstige) |
| Umfang/Format | Online-Ressource : online resource. |
| Persistent Identifier |
URN: urn:nbn:de:1111-2016111010880 DOI: 10.1186/s12885-016-2823-y |
| URL | http://dx.doi.org/10.1186/s12885-016-2823-y (Open Access) |
| Zeitliche Einordnung | Erscheinungsdatum: 2016 |
| Sprache(n) | Englisch (eng) |
| Beziehungen | Enthalten in: BMC cancer (Bd. 16, 10.10.2016, Nr. 1, date:12.2016: 1-8) |
| Online-Zugriff | Archivobjekt öffnen |

